银杏叶史话:中药/植物药研究开发的典范  

Ginkgo biloba leaves history: A model of research and development for Chinese materia medica/phytomedicine

作　　者：杨扬[1] 周斌[1] 赵文杰[1] 

机构地区：[1]中国医药工业研究总院上海医药工业研究院,上海201203

出　　处：《中草药》2016年第15期2579-2591,共13页Chinese Traditional and Herbal Drugs

基　　金：国家科技攻关计划项目(2001BA701A07-27)

摘　　要：从银杏叶的活性成分、药理作用、毒性与临床应用、各国药典质量标准的比较、药用发展史和我国银杏叶研究开发的现状进行详尽地阐述、分析与讨论。银杏叶的药用历史始于我国宋代,日本、德国的科学家在研究开发方面作出了开创性重要贡献,其发展史充分体现了锐意创新,成为中药/植物药研究开发的典范。我国银杏叶创新药物的研究已取得了长足进展,获得了重大成果,但我国银杏叶提取物及其制剂的质量标准与欧美存在明显差距,产业集中度较低。Summary in this paper, the active chemical constituents from Ginkgo biloba leaves （GBL）, their pharmacological effects, toxicity studies, clinical application, the comparison with the quality standard of the Pharmacopoeia, the history of medicinal development as well as the research and development of GBL in China were described, analyzed, and discussed in detail. GBL began to be recorded the medicinal value from the Song Dynasty in China. The scientists in research and development of GBL in Japanese and German have made significant pioneering contributions. The history of medicinal development of GBL has been fully embodied in the innovation, and has become a model for the research and development of Chinese materia medica and phytomedicine. The innovative drug research of GBL in China has made considerable progress, the significant results have been obtained. But the quality standard of Chinese GBL extract and its preparations have a significant difference with the European and American industries. The industry concentration is low.

关 键 词：银杏叶 中药 植物药 质量标准 创新药物 

分 类 号：R282.71[医药卫生—中药学]